Epstein-Barr Virus Infections Clinical Trial
| Verified date | October 2010 |
| Source | Rambam Health Care Campus |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Israel:IRB |
| Study type | Observational |
The purpose of this study is to study the prevalence of EBV, HCMV, HHV-6 in saliva and on the toothbrush patient with periodontitis.
| Status | Recruiting |
| Enrollment | 10 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 80 Years |
| Eligibility |
Inclusion Criteria: - Patient with peridontitis Exclusion Criteria: - Previous periodontal treatment in last 3 month - Toothbrushing disability |
Observational Model: Case-Only, Time Perspective: Cross-Sectional
| Country | Name | City | State |
|---|---|---|---|
| Israel | Department of Periodontology, School of Graduate Dentistry Rambam Health care campus | Haifa |
| Lead Sponsor | Collaborator |
|---|---|
| Rambam Health Care Campus |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The Prevelance Rate of the EBV, HCMV, HHV-6 in saliva | Check the EBV, HCMV, HHV-6 in saliva by PCR | 1 year | No |
| Secondary | change outcomes EBV, HCMV, HHV-6 in saliva before and after toothbrushing | Check the EBV, HCMV, HHV-6 in saliva by RC-PCR before and after toothbrushing | 1 year | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01256853 -
Modified Vaccinia Ankara (MVA) Vaccine Study
|
Phase 1 | |
| Completed |
NCT00070785 -
Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations
|
N/A | |
| Completed |
NCT00701922 -
Surveillance Study of Viral Infections Following Lung Transplantation
|
N/A | |
| Recruiting |
NCT02580539 -
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT03546101 -
Early Detection of Epstein-Barr Virus Related Disease.
|
||
| Recruiting |
NCT05183490 -
R-MVST Cells for Treatment of Viral Infections
|
Phase 1 | |
| Completed |
NCT00058812 -
Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts
|
Phase 1 | |
| Completed |
NCT01094405 -
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
|
Phase 2 | |
| Terminated |
NCT05305040 -
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
| Completed |
NCT02335437 -
Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents
|
N/A | |
| Completed |
NCT06002802 -
Study on Infectious Mononucleosis in Munich
|
||
| Recruiting |
NCT04507477 -
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03266653 -
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
|
Phase 2 | |
| Completed |
NCT00963248 -
EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients
|
N/A | |
| Enrolling by invitation |
NCT06027879 -
Anti-viral T-cell Therapy by Gamma Capture
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05592626 -
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02715752 -
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
|
N/A | |
| Completed |
NCT01070797 -
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)
|
Phase 1 | |
| Completed |
NCT00058604 -
Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).
|
Phase 1 | |
| Completed |
NCT00058591 -
Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)
|
Phase 1 |